OBJECTIVES: A number of newly developed treatments for advanced Neuroendocrine Tumours (NET) have demonstrated potential for significantly improving outcomes both in terms of disease progression and tolerability. There is however a paucity of available evidence detailing the quality of life impact of such therapies which is suitable for use in supporting economic evaluations. This study was designed to address this unmet need by capturing utility values for receiving NET treatment. METHODS: A number of health state descriptions were developed to characterise the typical quality of life challenges faced by NET patients undergoing therapy.  These vignettes were developed based upon the findings of a literature review, in-depth interviews with patients (n=5) and discussions with experienced NET specialists (clinicians n=5, oncology nurse n=1).  The states described stable and progressive disease with a range of common treatment related grade III/IV toxicities (stomatitis, rash, diarrhoea, nausea/vomiting, hyperglycaemia, thrombocytopenia, hand & foot syndrome and pneumonitis).  One hundred members of the UK general public rated each state in a time trade-off (TTO) interview.  The TTO exercise explores participants’ willingness to trade overall survival against changes in quality of life and therefore provides an indication of its value in that state. RESULTS: Values suitable for both pancreatic and carcinoid NET treatment are presented.  Stable disease had a reported utility value of 0.77 whilst progressive disease was associated with a marked decline and a value of 0.62.  The impact of toxicities was variable ranging from stable disease + hyperglycaemia (0.78) to stable disease + stomatitis (0.56). CONCLUSIONS: This study characterises the burden associated with receiving NET treatment, related adverse events and disease progression.  It demonstrates the considerable value of therapies offering reduced toxicity and the prospect of delaying progression in terms of preserving quality of life. These values could be used in establishing the cost-effectiveness of future treatments.